The upgrade from Neutral to Buy and the raised price target from $4.5 to $8 by Alliance Global Partners analyst James Molloy indicates a positive outlook for Alimera Sciences. This is likely to have a positive short-term impact on the stock price as investors may see this as a signal to buy.